JP2022051744A5 - - Google Patents

Download PDF

Info

Publication number
JP2022051744A5
JP2022051744A5 JP2022001433A JP2022001433A JP2022051744A5 JP 2022051744 A5 JP2022051744 A5 JP 2022051744A5 JP 2022001433 A JP2022001433 A JP 2022001433A JP 2022001433 A JP2022001433 A JP 2022001433A JP 2022051744 A5 JP2022051744 A5 JP 2022051744A5
Authority
JP
Japan
Prior art keywords
cells
seq
antigen receptor
chimeric antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022001433A
Other languages
English (en)
Japanese (ja)
Other versions
JP7252379B2 (ja
JP2022051744A (ja
Filing date
Publication date
Priority claimed from JP2017529682A external-priority patent/JP7098325B2/ja
Application filed filed Critical
Publication of JP2022051744A publication Critical patent/JP2022051744A/ja
Publication of JP2022051744A5 publication Critical patent/JP2022051744A5/ja
Application granted granted Critical
Publication of JP7252379B2 publication Critical patent/JP7252379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022001433A 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞 Active JP7252379B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462088423P 2014-12-05 2014-12-05
US62/088,423 2014-12-05
JP2017529682A JP7098325B2 (ja) 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞
PCT/US2015/064303 WO2016090369A1 (en) 2014-12-05 2015-12-07 Cs1 targeted chimeric antigen receptor-modified t cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017529682A Division JP7098325B2 (ja) 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞

Publications (3)

Publication Number Publication Date
JP2022051744A JP2022051744A (ja) 2022-04-01
JP2022051744A5 true JP2022051744A5 (https=) 2022-07-12
JP7252379B2 JP7252379B2 (ja) 2023-04-04

Family

ID=55069093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529682A Expired - Fee Related JP7098325B2 (ja) 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞
JP2022001433A Active JP7252379B2 (ja) 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017529682A Expired - Fee Related JP7098325B2 (ja) 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞

Country Status (12)

Country Link
US (3) US10821161B2 (https=)
EP (2) EP3227315B1 (https=)
JP (2) JP7098325B2 (https=)
KR (1) KR102558502B1 (https=)
CN (2) CN114085856A (https=)
AU (2) AU2015357485B2 (https=)
BR (1) BR112017011893A2 (https=)
CA (1) CA2969704C (https=)
IL (3) IL290459B2 (https=)
MX (2) MX384964B (https=)
RU (1) RU2727451C2 (https=)
WO (1) WO2016090369A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
KR102558502B1 (ko) * 2014-12-05 2023-07-20 시티 오브 호프 Cs1 표적화된 키메라 항원 수용체-변형된 t 세포
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
TWI795133B (zh) 2016-04-01 2023-03-01 美商凱特製藥公司 Bcma結合分子類及彼等之用途
CA3019650C (en) 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
AU2017291262A1 (en) 2016-06-30 2019-01-03 F. Hoffmann-La Roche Ag Improved adoptive T-cell therapy
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
US20190263928A1 (en) * 2016-09-30 2019-08-29 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
MX2019011225A (es) * 2017-03-20 2020-01-21 Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
AU2018257894A1 (en) 2017-04-24 2019-10-31 Kite Pharma, Inc. Humanized antigen-binding domains against CD19 and methods of use
CN110573177A (zh) * 2017-04-28 2019-12-13 尤利乌斯·马克西米利安维尔茨堡大学 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car)
EP3661511A1 (en) * 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
IL272552B2 (en) 2017-08-11 2023-09-01 Idac Holdings Inc Traffic routing and switching between multiple access networks
US12258580B2 (en) * 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
RS67119B1 (sr) * 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CA3177757A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN112166193A (zh) * 2018-05-21 2021-01-01 生物权威(英国)有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
EP3830133A1 (en) 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
CN114051532A (zh) * 2019-05-24 2022-02-15 希望之城公司 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞
WO2020254591A1 (en) * 2019-06-19 2020-12-24 Julius-Maximilians-Universität Würzburg Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
CA3184784A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
EP4192873A1 (en) * 2020-08-10 2023-06-14 Julius-Maximilians-Universität Würzburg Siglec-6-binding polypeptides
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN117242090A (zh) * 2021-03-30 2023-12-15 希望之城公司 CAR T细胞疗法和IFNγ
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药(上海)有限公司 Cs1工程化细胞及其组合物
WO2023107898A1 (en) * 2021-12-06 2023-06-15 The Children's Hospital Of Philadelphia Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN119095881A (zh) * 2022-03-25 2024-12-06 豪夫迈·罗氏有限公司 经改善的嵌合受体
CN120344563A (zh) * 2022-12-02 2025-07-18 广州荔泰生物科技有限公司 人cs1 car-t细胞
CN119019554B (zh) * 2023-05-25 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486572B1 (en) 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
GB0523954D0 (en) 2005-11-24 2006-01-04 Ucb Celltech Bioassays
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
RU2644242C2 (ru) * 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
CN105377897A (zh) 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
CN113307880B (zh) * 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US20170051037A1 (en) * 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
KR102558502B1 (ko) 2014-12-05 2023-07-20 시티 오브 호프 Cs1 표적화된 키메라 항원 수용체-변형된 t 세포
MX2019011225A (es) * 2017-03-20 2020-01-21 Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.

Similar Documents

Publication Publication Date Title
JP2022051744A5 (https=)
JP2022017333A5 (https=)
US20220170097A1 (en) Car t cell transcriptional atlas
JP2019511236A5 (https=)
RU2016143389A (ru) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
JP2019509029A5 (https=)
JP2022101658A5 (https=)
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
US20240082372A1 (en) Immunotherapy targeting tumor neoantigenic peptides
JP2017537627A5 (https=)
CN109415687A (zh) 嵌合抗原受体t细胞组合物
EP3870600A1 (en) Er tunable protein regulation
JP2021500889A5 (https=)
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
CA3001859A1 (en) Compositions and methods for inhibition of lineage specific antigens
JP2016538855A5 (https=)
CN109328230A (zh) 嵌合同种异体抗原受体t细胞的组合物和方法
JP2018516082A5 (https=)
JP2022522231A5 (https=)
JP2016514457A5 (https=)
WO2022189620A1 (en) Transmembrane neoantigenic peptides
CN111601882A (zh) 工程化的免疫细胞的应用和生产
CA3204211A1 (en) Chimeric receptor therapy
JP2022512538A (ja) Ebv関連がんの処置のための抗lmp2 tcr-t細胞療法
JP2018023397A5 (https=)